The medication prescribed to help you caused a heart attack. The drug for your depression led to suicidal thoughts. The treatment for one condition caused permanent damage to another organ system. Pharmaceutical companies profit enormously from drugs that sometimes cause serious harm, and when those companies fail to adequately test or warn about dangerous side effects, Georgia law provides remedies for injured patients.
Product Liability for Pharmaceuticals
Pharmaceutical products are subject to Georgia’s product liability law under O.C.G.A. § 51-1-11, but drugs present unique challenges compared to other products. Most drug injury claims focus on failure to warn rather than manufacturing or design defects.
Manufacturing defects occur when individual batches of medication are contaminated or improperly formulated. These cases are relatively straightforward but less common because drug manufacturing is heavily regulated.
Design defect claims allege the drug’s formula itself is unreasonably dangerous. These claims face significant hurdles because courts generally defer to FDA approval as evidence that drugs are adequately designed for their intended purpose.
Failure to warn claims dominate pharmaceutical litigation. Even properly manufactured drugs with FDA-approved formulas may be unreasonably dangerous if manufacturers fail to warn prescribers and patients of known or knowable risks.
The Learned Intermediary Doctrine
Georgia follows the learned intermediary doctrine for prescription drugs. Under this rule, drug manufacturers satisfy their warning duty by providing adequate warnings to prescribing physicians rather than directly to patients.
The physician serves as an intermediary between manufacturer and patient. Manufacturers must give physicians complete information about drug risks, and physicians decide what to tell patients based on their individual situations.
This doctrine means pharmaceutical claims typically focus on whether the manufacturer’s warnings to physicians were adequate, not whether the patient personally received warnings. If the manufacturer’s label disclosed the risk, claims become difficult even if the individual patient wasn’t told.
The learned intermediary doctrine doesn’t apply to direct-to-consumer advertising. When manufacturers advertise directly to patients, they assume some duty to warn consumers directly about risks their advertisements encourage people to seek.
Inadequate Warning Claims
Failure to warn claims require proving the manufacturer knew or should have known about the risk, the manufacturer’s warnings were inadequate to convey the risk’s nature and extent, and the inadequate warning caused the plaintiff’s injury.
Warning adequacy is measured against what a reasonable physician would need to know to make prescribing decisions. Buried fine print, understated risks, and failure to update warnings as new information emerges can all establish inadequacy.
Causation in warning cases requires showing that adequate warnings would have changed the prescriber’s decision. If the physician would have prescribed the drug anyway even with better warnings, causation fails. Alternatively, if the physician wasn’t even aware of the warnings provided, the inadequacy didn’t cause the injury.
Concealed Research and Fraud
The most serious pharmaceutical cases involve manufacturers who concealed negative research or misrepresented safety data. Hiding clinical trial results showing dangerous side effects, manipulating data to minimize apparent risks, and suppressing post-marketing reports of adverse events have all been documented in major drug cases.
When concealment is proven, plaintiffs may recover punitive damages in addition to compensatory damages. Georgia allows punitive damages when defendants acted with willful misconduct, malice, or conscious indifference to consequences.
Evidence of concealment typically emerges through discovery of internal company documents. Pharmaceutical cases often involve massive document production revealing what company scientists knew and when they knew it.
FDA Approval and Preemption
Drug manufacturers frequently argue that FDA approval preempts state law failure-to-warn claims. If the FDA approved their labeling, they argue, state courts can’t second-guess those decisions.
Supreme Court decisions have clarified preemption limits. Federal law preempts state claims that would require manufacturers to add warnings the FDA specifically prohibited. But state claims aren’t preempted when manufacturers could have added warnings under FDA regulations and simply chose not to.
For brand-name drugs, manufacturers can generally strengthen warnings without prior FDA approval. Claims that manufacturers should have provided stronger warnings typically survive preemption challenges.
Generic drug preemption is broader. Generic manufacturers must use the same labeling as brand-name drugs and can’t change warnings unilaterally. This has led courts to dismiss many generic drug failure-to-warn claims as preempted, though litigation continues over this issue.
Common Drug Injury Categories
Pharmaceutical injury litigation has targeted various drug categories.
Cardiovascular risks have prompted litigation involving pain medications like Vioxx that increased heart attack risk, diabetes drugs affecting cardiac health, and other medications with unexpected cardiovascular effects.
Psychiatric effects including suicidal ideation from antidepressants, particularly in young patients, have generated substantial litigation and led to black box warnings.
Cancer links have been alleged for various medications, including heartburn drugs potentially increasing stomach cancer risk and diabetes medications with bladder cancer associations.
Birth defects from medications taken during pregnancy have supported claims when manufacturers failed to adequately warn of teratogenic risks.
Organ damage including liver failure, kidney damage, and other organ toxicity has prompted litigation when manufacturers minimized these risks in labeling.
Expert Requirements in Drug Cases
Georgia’s O.C.G.A. § 51-1-11 requires expert affidavits in product liability claims involving failure to warn. The affidavit must come from an expert qualified to testify about pharmaceutical warnings, drug safety, and causation.
Medical experts establish that the drug caused the plaintiff’s injury and that the injury was a known or knowable risk at the time of marketing. Regulatory experts may address whether warnings met industry standards and FDA requirements. Epidemiological experts analyze population-level data about drug risks.
Drug injury cases are expert-intensive, often requiring multiple specialists to address different aspects of liability and causation.
Class Actions and Mass Torts
Pharmaceutical cases involving widely used drugs often proceed as class actions or mass tort litigation. When thousands of people are injured by the same drug, consolidation creates efficiency.
Multidistrict litigation (MDL) consolidates federal cases before a single judge for pretrial proceedings. Bellwether trials in MDL proceedings test case strength and inform settlement negotiations.
Class actions may certify for settlement purposes even when trial certification isn’t appropriate. Settlement classes allow comprehensive resolution affecting all claimants.
Individual claims remain possible outside consolidated proceedings, but practical considerations often favor joining larger litigation.
Statute of Repose Issues
Georgia’s ten-year statute of repose for product liability creates challenges for latent drug injuries. Drugs taken more than ten years before injury manifestation may fall outside the repose period.
However, the failure-to-warn exception may extend claims beyond repose when manufacturers knew of dangers and failed to disclose them. This exception is particularly relevant for drugs with concealed safety information.
Determining when the repose period begins can be complex for drugs taken over extended periods. Different doses may have different repose dates, affecting which exposures support viable claims.
Georgia’s Limitations Period
The two-year statute of limitations begins when plaintiffs knew or should have known their injuries were caused by the drug. For conditions with latent onset, this may be years after drug exposure.
Discovery rule extensions help plaintiffs who couldn’t have known the drug-injury connection immediately. But plaintiffs who ignored obvious symptoms or failed to investigate reasonably may lose discovery arguments.
Pharmaceutical manufacturers face liability when inadequate warnings contribute to patient injuries. Georgia law provides remedies, but drug cases involve complex expert requirements and defenses including preemption. This information provides general guidance and should not substitute for consultation with a Georgia pharmaceutical liability attorney about your specific situation.